{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:45:12Z","timestamp":1777639512542,"version":"3.51.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Nature Science Foundation for Distinguished Young Scholars of Sichuan","award":["2023NSFSC1971"],"award-info":[{"award-number":["2023NSFSC1971"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460813"],"award-info":[{"award-number":["82460813"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00210-025-04352-z","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T23:51:00Z","timestamp":1750204260000},"page":"17675-17693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging trends in anticoagulation therapy: a bibliometric analysis of DOACs and endogenous coagulation pathway inhibitors"],"prefix":"10.1007","volume":"398","author":[{"given":"Zhe","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xirui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangyan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"4352_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s12028-016-0248-8","volume":"26","author":"RA Abdoellakhan","year":"2017","unstructured":"Abdoellakhan RA, Miah IP, Khorsand N, Meijer K, Jellema K (2017) Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage: a retrospective analysis. Neurocrit Care 26:64\u201369. https:\/\/doi.org\/10.1007\/s12028-016-0248-8","journal-title":"Neurocrit Care"},{"key":"4352_CR2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382:1599\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1915103","journal-title":"N Engl J Med"},{"key":"4352_CR3","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s11239-024-02972-5","volume":"57","author":"AE Ali","year":"2024","unstructured":"Ali AE, Becker RC (2024) Factor XI: structure, function and therapeutic inhibition. J Thromb Thrombolysis 57:1315\u20131328. https:\/\/doi.org\/10.1007\/s11239-024-02972-5","journal-title":"J Thromb Thrombolysis"},{"key":"4352_CR4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/bloodadvances.2020003560","volume":"5","author":"JP Bassand","year":"2021","unstructured":"Bassand JP, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F et al (2021) Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv 5:1081\u20131091. https:\/\/doi.org\/10.1182\/bloodadvances.2020003560","journal-title":"Blood Adv"},{"key":"4352_CR5","doi-asserted-by":"publisher","first-page":"E426","DOI":"10.1016\/S2352-3026(16)30079-5","volume":"3","author":"H Cohen","year":"2016","unstructured":"Cohen H, Hunt BJ, Efthymiou M, Arachchillage DRJ, Mackie IJ, Clawson S et al (2016) Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial. Lancet Haematology 3:E426\u2013E436","journal-title":"Lancet Haematology"},{"key":"4352_CR6","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","volume":"43","author":"JP Collet","year":"2022","unstructured":"Collet JP, Van Belle E, Thiele H, Berti S, Lhermusier T, Manigold T et al (2022) Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J 43:2783\u20132797. https:\/\/doi.org\/10.1093\/eurheartj\/ehac242","journal-title":"Eur Heart J"},{"key":"4352_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151. https:\/\/doi.org\/10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"4352_CR8","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","volume":"380","author":"SJ Connolly","year":"2019","unstructured":"Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH et al (2019) Full study report of Andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 380:1326\u20131335. https:\/\/doi.org\/10.1056\/NEJMoa1814051","journal-title":"N Engl J Med"},{"key":"4352_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1055\/a-1450-8178","volume":"121","author":"J Douxfils","year":"2021","unstructured":"Douxfils J, Adcock DM, Bates SM, Favaloro EJ, Gouin-Thibault I, Guillermo C et al (2021) 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost 121:1008\u20131020. https:\/\/doi.org\/10.1055\/a-1450-8178","journal-title":"Thromb Haemost"},{"key":"4352_CR10","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","volume":"124","author":"ES Eerenberg","year":"2011","unstructured":"Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573\u20131579. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.029017","journal-title":"Circulation"},{"key":"4352_CR11","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ et al (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:1206\u20131214. https:\/\/doi.org\/10.1056\/NEJMoa1300615","journal-title":"N Engl J Med"},{"key":"4352_CR12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1160\/TH09-10-0734","volume":"103","author":"RJ Fonseca","year":"2010","unstructured":"Fonseca RJ, Oliveira SN, Pomin VH, Mecawi AS, Araujo IG, Mourao PA (2010) Effects of oversulfated and fucosylated chondroitin sulfates on coagulation. Challenges for the study of anticoagulant polysaccharides. Thromb Haemost 103:994\u20131004. https:\/\/doi.org\/10.1160\/TH09-10-0734","journal-title":"Thromb Haemost"},{"key":"4352_CR13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"4352_CR14","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/s0140-6736(14)61685-8","volume":"385","author":"JN Goldstein","year":"2015","unstructured":"Goldstein JN, Refaai MA, Milling TJ, Lewis B, Goldberg-Alberts R, Hug BA et al (2015) Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 385:2077\u20132087. https:\/\/doi.org\/10.1016\/s0140-6736(14)61685-8","journal-title":"Lancet"},{"key":"4352_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11886-023-01858-x","volume":"25","author":"A G\u00f3mez-Outes","year":"2023","unstructured":"G\u00f3mez-Outes A, Su\u00e1rez-Gea ML, Lecumberri R (2023) When and how to use reversal agents for direct oral anticoagulants? Curr Cardiol Rep 25:371\u2013380. https:\/\/doi.org\/10.1007\/s11886-023-01858-x","journal-title":"Curr Cardiol Rep"},{"key":"4352_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/s-0038-1627480","volume":"118","author":"RC Gosselin","year":"2018","unstructured":"Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I et al (2018) International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost 118:437\u2013450. https:\/\/doi.org\/10.1055\/s-0038-1627480","journal-title":"Thromb Haemost"},{"key":"4352_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992. https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"4352_CR18","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1093\/eurheartj\/ehab648","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC (vol 42, pg 373, 2021). Eur Heart J 42:4194\u20134194. https:\/\/doi.org\/10.1093\/eurheartj\/ehab648","journal-title":"Eur Heart J"},{"key":"4352_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","volume":"78","author":"C Hsu","year":"2021","unstructured":"Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI (2021) Factor XI inhibition to uncouple thrombosis from hemostasis JACC Review Topic of the Week. J Am Coll Cardiol 78:625\u2013631. https:\/\/doi.org\/10.1016\/j.jacc.2021.06.010","journal-title":"J Am Coll Cardiol"},{"key":"4352_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/rth2.12517","volume":"5","author":"R Ikesaka","year":"2021","unstructured":"Ikesaka R, Siegal D, Mallick R, Wang TF, Witham D, Webb C et al (2021) Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): a two-center open-label pilot randomized controlled trial. Res Pract Thromb Haemost 5:6. https:\/\/doi.org\/10.1002\/rth2.12517","journal-title":"Res Pract Thromb Haemost"},{"key":"4352_CR21","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"E Investigators","year":"2010","unstructured":"Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499\u20132510. https:\/\/doi.org\/10.1056\/NEJMoa1007903","journal-title":"N Engl J Med"},{"key":"4352_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"E-P Investigators","year":"2012","unstructured":"Investigators E-P, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287\u20131297. https:\/\/doi.org\/10.1056\/NEJMoa1113572","journal-title":"N Engl J Med"},{"key":"4352_CR23","doi-asserted-by":"publisher","first-page":"E285","DOI":"10.1161\/cir.0000000000000719","volume":"140","author":"CT January","year":"2019","unstructured":"January CT (2019) 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society (vol 140, e125, 2019). Circ 140:E285\u2013E285. https:\/\/doi.org\/10.1161\/cir.0000000000000719","journal-title":"Circ"},{"key":"4352_CR24","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1111\/bcp.15230","volume":"88","author":"D Kubitza","year":"2022","unstructured":"Kubitza D, Heckmann M, Distler J, Koechel A, Schwers S, Kanefendt F (2022) Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study. Br J Clin Pharmacol 88:3447\u20133462. https:\/\/doi.org\/10.1111\/bcp.15230","journal-title":"Br J Clin Pharmacol"},{"key":"4352_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.blre.2019.100615","volume":"39","author":"LS Lin","year":"2020","unstructured":"Lin LS, Zhao LY, Gao N, Yin RH, Li SJ, Sun HF et al (2020) From multi-target anticoagulants to DOACs, and intrinsic coagulation factor inhibitors. Blood Rev 39:9. https:\/\/doi.org\/10.1016\/j.blre.2019.100615","journal-title":"Blood Rev"},{"issue":"4","key":"4352_CR26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/md19040212","volume":"19","author":"S Liu","year":"2021","unstructured":"Liu S, Zhang T, Sun H, Lin L, Gao N, Wang W et al (2021) Pharmacokinetics and pharmacodynamics of a depolymerized glycosaminoglycan from Holothuria fuscopunctata, a novel anticoagulant candidate, in rats by bioanalytical methods. Mar Drugs 19(4):212. https:\/\/doi.org\/10.3390\/md19040212","journal-title":"Mar Drugs"},{"key":"4352_CR27","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021011725","volume":"138","author":"CU Lorentz","year":"2021","unstructured":"Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD et al (2021) The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood 138:2173\u20132184","journal-title":"Blood"},{"key":"4352_CR28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA et al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5:927\u2013974. https:\/\/doi.org\/10.1182\/bloodadvances.2020003442","journal-title":"Blood Adv"},{"key":"4352_CR29","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1056\/NEJM200003093421004","volume":"342","author":"JC Meijers","year":"2000","unstructured":"Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR (2000) High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 342:696\u2013701. https:\/\/doi.org\/10.1056\/NEJM200003093421004","journal-title":"N Engl J Med"},{"key":"4352_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1161\/atvbaha.116.308595","volume":"37","author":"KF Nickel","year":"2017","unstructured":"Nickel KF, Long AT, Fuchs TA, Butler LM, Renn\u00e9 T (2017) Factor XII as a therapeutic target in thromboembolic and inflammatory diseases. Arterioscler Thromb Vasc Biol 37:13. https:\/\/doi.org\/10.1161\/atvbaha.116.308595","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4352_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2022.02.009","volume":"346","author":"E Paszek","year":"2022","unstructured":"Paszek E, Pociask E, Zabczyk M, Piorkowski A, Butenas S, Legutko J et al (2022) Active factor XI is associated with the risk of cardiovascular events in stable coronary artery disease patients. Atherosclerosis 346:124\u2013132. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.02.009","journal-title":"Atherosclerosis"},{"key":"4352_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan GH, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"4352_CR33","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132:1365\u20131371. https:\/\/doi.org\/10.1182\/blood-2018-04-848333","journal-title":"Blood"},{"key":"4352_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ahj.2019.02.001","volume":"212","author":"ED Peterson","year":"2019","unstructured":"Peterson ED, Ashton V, Chen YW, Wu BC, Spyropoulos AC (2019) Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J 212:113\u2013119. https:\/\/doi.org\/10.1016\/j.ahj.2019.02.001","journal-title":"Am Heart J"},{"key":"4352_CR35","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/s0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS et al (2022) Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 399:1383\u20131390. https:\/\/doi.org\/10.1016\/s0140-6736(22)00456-1","journal-title":"Lancet"},{"key":"4352_CR36","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/circulationaha.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K et al (2022) Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circ 146:1735\u20131745. https:\/\/doi.org\/10.1161\/circulationaha.121.054990","journal-title":"Circ"},{"key":"4352_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511\u2013520. https:\/\/doi.org\/10.1056\/NEJMoa1502000","journal-title":"N Engl J Med"},{"key":"4352_CR38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack","year":"2017","unstructured":"Pollack CV, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA et al (2017) Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 377:431\u2013441. https:\/\/doi.org\/10.1056\/NEJMoa1707278","journal-title":"N Engl J Med"},{"key":"4352_CR39","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1016\/s2352-3026(14)70018-3","volume":"1","author":"MH Prins","year":"2014","unstructured":"Prins MH, Lensing AWA, Brighton TA, Lyons RM, Rehm J, Trajanovic M et al (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1:E37\u2013E46. https:\/\/doi.org\/10.1016\/s2352-3026(14)70018-3","journal-title":"Lancet Haematol"},{"key":"4352_CR40","doi-asserted-by":"publisher","first-page":"E330","DOI":"10.1161\/cir.0000000000001115","volume":"146","author":"Rao","year":"2022","unstructured":"Rao (2022) A multicenter, phase 2, randomized, placebo- controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction ((vol 146, pg 1196, 2022). Circ 146:E330\u2013E330. https:\/\/doi.org\/10.1161\/cir.0000000000001115","journal-title":"Circ"},{"key":"4352_CR41","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378:615\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1711948","journal-title":"N Engl J Med"},{"key":"4352_CR42","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/s0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955\u2013962. https:\/\/doi.org\/10.1016\/s0140-6736(13)62343-0","journal-title":"Lancet"},{"key":"4352_CR43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1160\/TH10-05-0307","volume":"105","author":"O Salomon","year":"2011","unstructured":"Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U (2011) Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 105:269\u2013273. https:\/\/doi.org\/10.1160\/TH10-05-0307","journal-title":"Thromb Haemost"},{"key":"4352_CR44","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342\u20132352","journal-title":"N Engl J Med"},{"key":"4352_CR45","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ejmech.2018.02.047","volume":"148","author":"FN Shang","year":"2018","unstructured":"Shang FN, Gao N, Yin RH, Lin L, Xiao C, Zhou LT et al (2018) Precise structures of fucosylated glycosaminoglycan and its oligosaccharides as novel intrinsic factor Xase inhibitors. Eur J Med Chem 148:423\u2013435. https:\/\/doi.org\/10.1016\/j.ejmech.2018.02.047","journal-title":"Eur J Med Chem"},{"key":"4352_CR46","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1182\/blood-2005-07-3043","volume":"107","author":"JP Sheehan","year":"2006","unstructured":"Sheehan JP, Walke EN (2006) Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism. Blood 107:3876\u20133882. https:\/\/doi.org\/10.1182\/blood-2005-07-3043","journal-title":"Blood"},{"key":"4352_CR47","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/s0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T et al (2022) Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo- controlled, phase 2b trial. Lancet 400:997\u20131007. https:\/\/doi.org\/10.1016\/s0140-6736(22)01588-4","journal-title":"Lancet"},{"key":"4352_CR48","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","volume":"373","author":"DM Siegal","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ, Lu GM, Conley PB, Wiens BL et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413\u20132424. https:\/\/doi.org\/10.1056\/NEJMoa1510991","journal-title":"N Engl J Med"},{"key":"4352_CR49","doi-asserted-by":"publisher","first-page":"112796","DOI":"10.1016\/j.ejmech.2020.112796","volume":"207","author":"H Sun","year":"2020","unstructured":"Sun H, Gao N, Ren L, Liu S, Lin L, Zheng W et al (2020) The components and activities analysis of a novel anticoagulant candidate dHG-5. Eur J Med Chem 207:112796. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112796","journal-title":"Eur J Med Chem"},{"key":"4352_CR50","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1161\/circulationaha.118.036710","volume":"139","author":"SJ Van der Wall","year":"2019","unstructured":"Van der Wall SJ, Lopes RD, Aisenberg J, Reilly P, van Ryn J, Glund S et al (2019) Idarucizumab for dabigatran reversal in the management of patients with gastrointestinal bleeding. Circ 139:748\u2013756. https:\/\/doi.org\/10.1161\/circulationaha.118.036710","journal-title":"Circ"},{"issue":"12","key":"4352_CR51","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","volume":"124","author":"N Van Es","year":"2014","unstructured":"Van Es N, Coppens M, Schulman S, Middeldorp S, B\u00fcller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968\u20131975. https:\/\/doi.org\/10.1182\/blood-2014-04-571232","journal-title":"Blood"},{"key":"4352_CR52","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","volume":"385","author":"NM Van Mieghem","year":"2021","unstructured":"Van Mieghem NM, Unverdorben M, Hengstenberg C, M\u00f6llmann H, Mehran R, L\u00f3pez-Otero D et al (2021) Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med 385:2150\u20132160. https:\/\/doi.org\/10.1056\/NEJMoa2111016","journal-title":"N Engl J Med"},{"key":"4352_CR53","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Buller HR et al (2021) Abelacimab for prevention of venous thromboembolism. N Engl J Med 385:609\u2013617. https:\/\/doi.org\/10.1056\/NEJMoa2105872","journal-title":"N Engl J Med"},{"key":"4352_CR54","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1161\/cir.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH et al (2023) 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circ 148:E9\u2013E119. https:\/\/doi.org\/10.1161\/cir.0000000000001168","journal-title":"Circ"},{"key":"4352_CR55","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/s0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G et al (2019) Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 394:1335\u20131343. https:\/\/doi.org\/10.1016\/s0140-6736(19)31872-0","journal-title":"Lancet"},{"key":"4352_CR56","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","volume":"7","author":"M Walsh","year":"2022","unstructured":"Walsh M, Bethune C, Smyth A, Tyrwhitt J, Jung SW, Yu RZ et al (2022) Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD. Kidney Int Rep 7:200\u2013209. https:\/\/doi.org\/10.1016\/j.ekir.2021.11.011","journal-title":"Kidney Int Rep"},{"key":"4352_CR57","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1056\/NEJMc1715183","volume":"378","author":"X Wang","year":"2018","unstructured":"Wang X, Karnieg T (2018) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 378:484\u2013484","journal-title":"N Engl J Med"},{"key":"4352_CR58","doi-asserted-by":"publisher","first-page":"4717271","DOI":"10.1155\/2023\/4717271","volume":"2023","author":"J Wang","year":"2023","unstructured":"Wang J, Liu YX, Yan YD, Liu L, Zhang C, Pan MM et al (2023) Global research hotspots in venous thromboembolism anticoagulation: a knowledge-map analysis from 2012 to 2021. J Interv Cardiol 2023:4717271. https:\/\/doi.org\/10.1155\/2023\/4717271","journal-title":"J Interv Cardiol"},{"key":"4352_CR59","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","volume":"323","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR et al (2020) Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty the FOXTROT randomized clinical trial. J-J Am Med Assoc 323:130\u2013139. https:\/\/doi.org\/10.1001\/jama.2019.20687","journal-title":"J-J Am Med Assoc"},{"key":"4352_CR60","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","volume":"385","author":"JI Weitz","year":"2021","unstructured":"Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR et al (2021) Milvexian for the prevention of venous thromboembolism. N Engl J Med 385:2161\u20132172. https:\/\/doi.org\/10.1056\/NEJMoa2113194","journal-title":"N Engl J Med"},{"key":"4352_CR61","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/circresaha.115.306841","volume":"118","author":"AM Wendelboe","year":"2016","unstructured":"Wendelboe AM, Raskob GE (2016) Global burden of thrombosis epidemiologic aspects. Circ Res 118:1340\u20131347. https:\/\/doi.org\/10.1161\/circresaha.115.306841","journal-title":"Circ Res"},{"key":"4352_CR62","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejmech.2014.12.054","volume":"92","author":"M Wu","year":"2015","unstructured":"Wu M, Wen D, Gao N, Xiao C, Yang L, Xu L et al (2015) Anticoagulant and antithrombotic evaluation of native fucosylated chondroitin sulfates and their derivatives as selective inhibitors of intrinsic factor Xase. Eur J Med Chem 92:257\u2013269. https:\/\/doi.org\/10.1016\/j.ejmech.2014.12.054","journal-title":"Eur J Med Chem"},{"key":"4352_CR63","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1055\/s-0039-1681047","volume":"119","author":"C Xiao","year":"2019","unstructured":"Xiao C, Zhao L, Gao N, Wu M, Zhao J (2019) Nonasaccharide inhibits intrinsic factor Xase complex by binding to factor IXa and disrupting factor IXa-factor VIIIa interactions. Thromb Haemost 119:705\u2013715. https:\/\/doi.org\/10.1055\/s-0039-1681047","journal-title":"Thromb Haemost"},{"key":"4352_CR64","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","volume":"123","author":"JW Yau","year":"2014","unstructured":"Yau JW, Liao P, Fredenburgh JC, Stafford AR, Revenko AS, Monia BP et al (2014) Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123:2102\u20132107. https:\/\/doi.org\/10.1182\/blood-2013-12-540872","journal-title":"Blood"},{"key":"4352_CR65","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jcin.2022.01.285","volume":"15","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Si D, Zhang Q, Jin L, Zheng H, Qu M et al (2022) Prophylactic rivaroxaban therapy for left ventricular thrombus after anterior ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 15:861\u2013872. https:\/\/doi.org\/10.1016\/j.jcin.2022.01.285","journal-title":"JACC Cardiovasc Interv"},{"key":"4352_CR66","doi-asserted-by":"publisher","first-page":"8284","DOI":"10.1073\/pnas.1504229112","volume":"112","author":"LY Zhao","year":"2015","unstructured":"Zhao LY, Wu MY, Xiao C, Yang L, Zhou LT, Gao N et al (2015) Discovery of an intrinsic tenase complex inhibitor: pure nonasaccharide from fucosylated glycosaminoglycan. Proc Natl Acad Sci USA 112:8284\u20138289. https:\/\/doi.org\/10.1073\/pnas.1504229112","journal-title":"Proc Natl Acad Sci USA"},{"key":"4352_CR67","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1055\/s-0040-1708480","volume":"120","author":"L Zhou","year":"2020","unstructured":"Zhou L, Gao N, Sun H, Xiao C, Yang L, Lin L et al (2020a) Effects of native fucosylated glycosaminoglycan, its depolymerized derivatives on intrinsic factor Xase, coagulation, thrombosis, and hemorrhagic risk. Thromb Haemost 120:607\u2013619. https:\/\/doi.org\/10.1055\/s-0040-1708480","journal-title":"Thromb Haemost"},{"key":"4352_CR68","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40256-019-00362-4","volume":"20","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Ma JY, Zhu WG (2020b) Efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation across BMI categories: a systematic review and meta-analysis. Am J Cardiovasc Drugs 20:51\u201360. https:\/\/doi.org\/10.1007\/s40256-019-00362-4","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04352-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04352-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04352-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T04:30:35Z","timestamp":1764822635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04352-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4352"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04352-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This declaration is not applicable. No animal or human studies are presented in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}